Latest Monoclonal antibodies Stories
-- Subsequent entry biologic (SEB) medicine provides a lower-cost, high-quality, safe and effective therapy for rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA)
Clinical Study (003-011) to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination with Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD)
Simponi (golimumab) (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023 LONDON, March 26, 2015 /PRNewswire/ -- SummaryRheumatoid arthritis (RA) is a chronic
LONDON, March 26, 2015 /PRNewswire/ -- SummaryRheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints.
Study Expected to Complete in 4Q 2015 SAN JOSE, Calif., March 26, 2015 /PRNewswire/ -- Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to
HATFIELD, Pa., March 26, 2015 /PRNewswire/ -- Genisphere LLC, provider of the 3DNA(®) nanotechnology platform, reported today it has achieved specific immunodepletion of problematic Myo/Nog
DALLAS, March 24, 2015 /PRNewswire/ -- According to a new market research report " Protein Engineering Market by Technology (Rational Protein Design, Irrational Protein
- New data at AAD shows 7 out of 10 psoriasis patients who were PASI 75 responders at 52 weeks achieved clear to almost clear skin (PASI 90) after two years of Cosentyx 300 mg treatment
- Phase IIIb CLEAR study at AAD showed over 21% more psoriasis patients achieved clear to almost clear skin (PASI 90) with Cosentyx(TM) (secukinumab) compared to Stelara® (ustekinumab) at Week 16
DALLAS, March 19, 2015 /PRNewswire/ -- RnRMarketResearch.com adds "PharmaPoint: Rheumatoid Arthritis - US and 5EU Drug Forecast and Market Analysis to 2023" report provides
- Large; stout; burly.
More Images (1 images) »